ArticleFrontiers in microbiology2020
Ribotype Classification of
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Clostridioides difficile as a Zoonotic and Foodborne Pathogen: Reviewing the Global Evidence and South African Data.MicrobiologyOpen · 2026Review
- Pooled analyses of Clostridioides difficile vaccine trials identify baseline predictors for vaccine response.Scientific reports · 2026Article
- Comparative genomic analysis of Clostridioides difficile strains in Mexico: insights into virulence and resistance.Access microbiology · 2026Article
- Molecular epidemiology and antimicrobial resistance profiles ofFrontiers in microbiology · 2026Article
- Phenotypic analysis of variousApplied and environmental microbiology · 2025Article
- Healthcare-AssociatedMicroorganisms · 2025Article
- Phenotypic analysis of variousbioRxiv : the preprint server for biology · 2025Article
- Whole-genome sequencing of toxigenic Clostridioides difficile reveals multidrug resistance and virulence genes in strains of environmental and animal origin.BMC veterinary research · 2024Article
- De novo design of mini-protein binders broadly neutralizing Clostridioides difficile toxin B variants.Nature communications · 2024Article
- Comparison of toxin gene expression levels and molecular typing ofGastroenterology and hepatology from bed to bench · 2024Article
- Pathogenicity and virulence ofVirulence · 2023Review
- Update on Commonly Used Molecular Typing Methods forMicroorganisms · 2023Review
- Symptoms, Treatment, and Outcomes of COVID-19 Patients Coinfected withAntibiotics (Basel, Switzerland) · 2023Article
- Receptor binding mechanisms of Clostridioides difficile toxin B and implications for therapeutics development.The FEBS journal · 2023Review
- Prevalence of diagnostically-discrepantFrontiers in medicine · 2023Article
- Structure of the glucosyltransferase domain of TcdA in complex with RhoA provides insights into substrate recognition.Scientific reports · 2022Article
- Whole-Genome Sequencing Reveals the High Nosocomial Transmission and Antimicrobial Resistance of Clostridioides difficile in a Single Center in China, a Four-Year Retrospective Study.Microbiology spectrum · 2022Article
- Battling Enteropathogenic Clostridia: Phage Therapy forFrontiers in microbiology · 2022Review
- Structural basis for selective modification of Rho and Ras GTPases byScience advances · 2021Article
- Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.